Quest Laboratories Ltd
Incorporated in 1998, Quest Laboratories Ltd is a pharmaceutical manufacturer specializing in diverse therapeutic segments[1]
- Market Cap ₹ 144 Cr.
- Current Price ₹ 88.0
- High / Low ₹ 160 / 75.2
- Stock P/E 10.6
- Book Value ₹ 49.9
- Dividend Yield 0.00 %
- ROCE 26.9 %
- ROE 24.6 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 32.0%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 30 | 59 | 62 | 83 | 104 | |
| 29 | 53 | 54 | 67 | 88 | |
| Operating Profit | 1 | 6 | 8 | 16 | 16 |
| OPM % | 5% | 11% | 13% | 19% | 15% |
| 0 | 0 | 0 | 0 | 4 | |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 1 | 1 | 1 |
| Profit before tax | 1 | 6 | 7 | 14 | 19 |
| Tax % | 18% | 29% | 28% | 30% | 27% |
| 1 | 4 | 5 | 10 | 14 | |
| EPS in Rs | 8.45 | 8.28 | |||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| TTM: | 26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 49% |
| TTM: | 34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 32% |
| Last Year: | 25% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 12 | 16 |
| Reserves | 5 | 9 | 14 | 17 | 65 |
| 3 | 3 | 4 | 5 | 30 | |
| 9 | 22 | 28 | 27 | 10 | |
| Total Liabilities | 18 | 35 | 47 | 61 | 122 |
| 6 | 7 | 10 | 10 | 12 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 7 | 52 |
| 12 | 27 | 37 | 44 | 58 | |
| Total Assets | 18 | 35 | 47 | 61 | 122 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 1 | 3 | 4 | 3 | -23 | |
| -1 | -2 | -4 | -5 | -44 | |
| 0 | -0 | 0 | 2 | 67 | |
| Net Cash Flow | -0 | 1 | 0 | 0 | -0 |
Ratios
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 110 | 135 | 118 | 108 | 105 |
| Inventory Days | 12 | 9 | 97 | 113 | 99 |
| Days Payable | 119 | 140 | 215 | 144 | 26 |
| Cash Conversion Cycle | 3 | 4 | 1 | 77 | 178 |
| Working Capital Days | 9 | 14 | 27 | 58 | 72 |
| ROCE % | 55% | 47% | 57% | 27% |
Documents
Announcements
-
General Updates
6 October 2025 - Sep-2025 net sales Rs12,92,44,357 (-13.38% YoY); Apr-Sep sales Rs48,80,48,328 (+14.50%).
-
Analysts/Institutional Investor Meet/Con. Call Updates
6 October 2025 - One-on-one analyst meetings on 09 Oct 2025 at 03:00 PM with Nuvama, CAO Capital, Genuity; virtual, no UPSI.
-
Shareholders meeting
1 October 2025 - 27th AGM results: all four ordinary resolutions passed on 29 Sep 2025; 71.11% turnout, Anil Sabarwal re-appointed.
-
Trading Window
29 September 2025 - Trading window closed from Oct 1, 2025 until 48 hours after Sep 30, 2025 results announcement.
-
Shareholders meeting
29 September 2025 - 27th AGM on 29 Sep 2025: FY2024-25 accounts adopted; Anil Sabarwal reappointed; secretarial auditor appointed.
Business Overview:[1][2]
a) QLL specializes in manufacturing a wide range of pharmaceutical formulations, including antibiotics, antimalarials, anti-inflammatories, respiratory medications,
diabetes treatments, and more.
b) Company also produces a wide range of ethical, generic, and over-the-counter (OTC) drugs in various forms, including tablets, liquids, oral powders, ORS, ointments, and external liquids.
c) Quest offers facilities for institutional supplies, domestic ethical products, PCD, Contract manufacturing, and export, with
a focus on a wide range of specialized formulations and molecules
d) The company has 800+ Licensed Formulations, 272+ Active Products, 25cr.+Order Book from Myanmar